SHINE Technologies is a member of the Wisconsin Technology Council.
SHINE Technologies has submitted its drug master file to the FDA for a material used in precision cancer treatment.
The Janesville-based company yesterday announced the submission for non-carrier added lutetium-177 chloride, or Lu-177. This radiopharmaceutical is used alongside a cancer-seeking molecule to attack cancer cells, and is “especially useful” against prostate cancer, according to the release.
The filing covers detailed information about SHINE Technologies’ facilities and procedures involved with manufacturing, processing and storing the drug. The company made its first commercial sale of Lu-177 in 2020, according to an earlier release.
;
